查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1587436

美国伴同性动物保健市场规模、份额和趋势分析报告：按动物类型、按产品、按分销管道、按最终用途、按国家、细分市场预测，2025-2030 年

U.S. Companion Animal Health Market Size, Share & Trends Analysis Report By Animal Type (Dogs, Cats, Equine), By Product (Vaccines, Pharmaceuticals, Supplements), By Distribution Channel, By End Use, By Country, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

美国伴同性动物保健市场的成长与趋势：

预计2030年，美国伴同性动物保健市场规模将达到139.7亿美元，2025年至2030年复合年增长率预计为9.87%。

越来越多的宠物饲主为其伴同性动物寻求更好的医疗保健服务、更健康的优质食品以及优质的美容和培训服务，这是这个市场的主要驱动力。根据全国宠物主人调查，美国有 9,050 万家庭拥有宠物，其中 6,900 万家庭拥有狗。此外，高所得者约占总支出的60%。近年来，宠物拥有量显着成长。根据 HABRI（人类与动物关係研究倡议基金会）透露，这主要是因为宠物的存在让人们变得更健康、更快乐。

随着伴同性动物越来越受欢迎，人们对它们健康的担忧也越来越多，这与宠物保险有着直接的关联。目前，宠物保险仅占保险业的一小部分。勃林格殷格翰动物保健公司、Chewy、Elanco、MWI 动物保健公司、Covetrus 和 PetIQ 等主要企业宣布，他们正在努力在冠状病毒大流行期间实现更灵活的兽医检测。扩大远端医疗解决方案。

新疗法和伴同性动物疫苗的核准继续为该市场提供利润丰厚的成长机会。 COVID-19 危机进一步加速了电子商务、宠物保险、兽医远端医疗、护理点诊断测试和兽医实践数位化等持续采用趋势。

突破性的技术进步正在迅速改变宠物健康产业。这种扩张最大限度地发挥了成长潜力。公司正在宠物健康方面采取策略性倡议，包括采用巨量资料、穿戴式技术来监测宠物健康，以及纳入干细胞疗法。此外，现有企业正致力于扩大其投资组合。例如，Elanco 于 2019 年 8 月收购了拜耳公司的动物用药品部门。

美国已经获得了相当大的市场份额。该国所获得的份额主要归功于具有广泛扩大策略的知名市场参与者的存在。此外，企业发起的研发投资增加是关键的潜在成长要素之一，据估计，这也是美国占据大量份额的原因。

美国伴同性动物保健市场报告亮点

  • 按动物类型划分，由于宠物照护支出增加，尤其是在新兴市场，狗类细分市场在 2024 年以 40.57% 的最高收益占有率引领市场。
  • 从产品来看，由于延长宠物寿命的需求不断增长以及研发活动的活性化，製药业预计将在未来几年受到欢迎。
  • 从分销管道来看，由于宠物饲主的便利性提高，电子商务产业预计将在预测期内快速成长。
  • 按最终用途划分，医院和诊所行业以 2024 年 50.68% 的最大销售份额引领市场。兽医医院和诊所鼓励宠物饲主寻求有效的治疗，教育他们诊断和药物对宠物健康的价值。
  • Vetiquinol SA、Zoetis、默克、Ceva Sante Animale、勃林格殷格翰有限公司、Elanco 因其产品供应和强大的区域影响力而成为一些主要的市场参与企业。
  • 公司采用各种策略来获得竞争优势，包括新产品开发、联盟、併购、联盟和地理扩张。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章美国伴同性动物保健市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 配套市场前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
    • 市场机会分析
    • 市场问题分析
  • 美国伴同性动物保健市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
    • 法律规范
    • 价格分析
    • 产品平臺分析
    • 2018-2024 年美国宠物数量估计
    • COVID-19 影响分析

第四章美国伴同性动物保健市场：按动物类型的估计和趋势分析

  • 细分仪表板
  • 美国伴同性动物保健市场：2024 年和 2030 年按动物类型分類的波动分析和市场占有率
  • 狗
  • 猫
  • 马
  • 其他的

第五章美国伴同性动物保健市场：依产品类型估价和趋势分析

  • 细分仪表板
  • 美国伴同性动物保健市场：2024 年和 2030 年产品变异分析和市场占有率
  • 生物製药
    • 疫苗
    • 其他生物製药
  • 药品
    • 寄生剂
    • 抗感染
    • 发炎（药
    • 止痛药
    • 其他的
  • 补充品
  • 诊断
  • 其他的

第六章美国伴同性动物保健市场：依通路估算与趋势分析

  • 细分仪表板
  • 美国伴同性动物保健市场：2024 年和 2030 年分销管道变化分析和市场占有率
  • 零售
  • 电子商务
  • 医院/诊所药房

第七章美国伴同性动物保健市场：最终用途的估计和趋势分析

  • 细分仪表板
  • 美国伴同性动物保健市场：2024 年和 2030 年最终用途变化分析和市场占有率
  • 医院/诊所
  • 照护现场
  • 其他的

第八章 竞争格局

  • 市场参与企业分类
  • 企业市场分析/堆图分析
  • 公司简介
    • Merck &Co., Inc.
    • Elanco
    • Boehringer Ingelheim GmbH
    • Ceva Sante Animale
    • Zoetis
    • Virbac
    • IDEXX
    • Mars Inc.
    • Dechra Pharmaceuticals Plc（EQT）
    • Vetoquinol SA
Product Code: GVR-3-68038-960-9

U.S. Companion Animal Health Market Growth & Trends:

The U.S. companion animal health market size is estimated to reach at USD 13.97 billion in 2030 and is projected to grow at a CAGR of 9.87% from 2025 to 2030. The rising number of pet owners seeking better healthcare services, healthier quality foods, and high-end grooming and training services for their companion animals is a major driver for this market. According to theNational Pet Owners Survey, 90.5 million families in the U.S. own a pet, out of which 69.0 million own a dog. Moreover, high-income families amounted to approximately 60% of the total spending. In recent years, pet adoption has shown immense growth. This is primarily attributed to the fact that people are healthier and happier in the presence of pets, as found by the Human-Animal Bond Research Initiative Foundation (HABRI).

With the rising adoption of companion animals and growing concerns over their health, there comes a direct association with pet insurance. Presently, pet insurance accounts for a small segment in the insurance industry. The Covid-19 pandemic positively impacted the market growth in the U.S. Key players such as Boehringer Ingelheim Animal Health, Chewy, Elanco, MWI Animal Health, Covetrus, and PetIQ focused on expanding their telemedicine solutions into the market as governments relaxed governance to enable more flexible veterinary examinations during the coronavirus pandemic.

Approval of novel therapeutics and companion animal vaccines continues to present this market with lucrative growth opportunities. Ongoing trends for the adoption of e-commerce, pet insurance, veterinary telemedicine, point of care diagnostic testing, and digitalization of veterinary practices are further accelerated by the crisis of COVID-19.

Groundbreaking technological advances are rapidly transforming the pet health industry. These expansions are maximizing the potential for growth. Companies are taking strategic initiatives in pet health, such as the adoption of big data, wearable technologies to monitor pet health, and the inclusion of stem cell therapy. Moreover, established players are focusing on expanding their portfolios. For instance, Elanco acquired Bayer AG's animal health business unit in August 2019.

The U.S. captured a substantial share of the market. The share attained by this country is primarily a consequence of the presence of prominent market players undertaking extensive expansion strategies. Moreover, the increasing number of R&D investments initiated by the companies is one of the key potential growth factors presumed to be responsible for the sizeable share garnered by the U.S.

U.S. Companion Animal Health Market Report Highlights:

  • Based on animal type, the dogs segment led the market with the largest revenue share of 40.57% in 2024 due to the increasing spending on pet care, specifically in developed regions.
  • By product, the pharmaceuticals segment is expected to gain popularity in the coming years owing to the growing demand to increase pet longevity and rising R&D activities.
  • On the basis of distribution channel, the e-commerce segment is anticipated to witness rapid growth over the forecast period due to the increased convenience offered to pet owners.
  • Based on end use, the hospitals & clinics segment led the market with the largest revenue share of 50.68% in 2024. Veterinary hospitals and clinics encourage pet owners to seek out effective treatments by educating them on the value of diagnostics and medication for their pet's health.
  • Vetiquinol S.A., Zoetis, Merck, Ceva Sante Animale, Boehringer Ingelheim GmbH, and Elanco are some of the major market participants due to their product offerings and strong regional presence.
  • Companies are adopting various strategies to gain competitive advantages, such as new product development, partnerships, mergers and acquisitions, collaborations, and regional expansion.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Research Methodology
  • 1.3. Information Procurement
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Companion Animal Health Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising prevalence of pet diseases
      • 3.2.1.2. Growing uptake of pet insurance
      • 3.2.1.3. Increasing pet population
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High cost of advanced treatment
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenge Analysis
  • 3.3. U.S. Companion Animal Health Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political & Legal landscape
      • 3.3.2.2. Economic and Social landscape
      • 3.3.2.3. Technological landscape
    • 3.3.3. Regulatory Framework
    • 3.3.4. Pricing Analysis
    • 3.3.5. Product Pipeline Analysis
    • 3.3.6. Estimated Number of pet popultion in U.S., 2018-2024
    • 3.3.7. COVID-19 Impact Analysis

Chapter 4. U.S. Companion Animal Health Market: Animal type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Companion Animal Health Market: Animal type Movement Analysis & Market Share, 2024 & 2030
  • 4.3. Dogs
    • 4.3.1. Dogs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Cats
    • 4.4.1. Cats Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Equine
    • 4.5.1. Equine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. Companion Animal Health Market: Product Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Companion Animal Health Market: Product Movement Analysis & Market Share, 2024 & 2030
  • 5.3. Biologics
    • 5.3.1. Biologics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.2. Vaccines
      • 5.3.2.1. Vaccines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 5.3.2.2. Modified/ Attenuated Live
        • 5.3.2.2.1. Modified/ Attenuated Live Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 5.3.2.3. Inactivated (Killed)
        • 5.3.2.3.1. Inactivated (Killed) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 5.3.2.4. Other Vaccines
        • 5.3.2.4.1. Other Vaccines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.3. Other Biologics
      • 5.3.3.1. Other Biologics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Pharmaceuticals
    • 5.4.1. Pharmaceuticals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.2. Parasiticides
      • 5.4.2.1. Parasiticides Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.3. Anti-infectives
      • 5.4.3.1. Anti-Infectives Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.4. Anti-Inflammatory
      • 5.4.4.1. Anti-Inflammatory Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.5. Analgesics
      • 5.4.5.1. Analgesics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.6. Others
      • 5.4.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Supplements
    • 5.5.1. Supplements Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Diagnostics
    • 5.6.1. Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. U.S. Companion Animal Health Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Companion Animal Health Market: Distribution Channel Movement Analysis & Market Share, 2024 & 2030
  • 6.3. Retail
    • 6.3.1. Retail Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. E-Commerce
    • 6.4.1. E-Commerce Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Hospital/ Clinic Pharmacies
    • 6.5.1. Hospital/ Clinic Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. U.S. Companion Animal Health Market: End Use Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. U.S. Companion Animal Health Market: End Use Movement Analysis & Market Share, 2024 & 2030
  • 7.3. Hospitals & Clinics
    • 7.3.1. Hospitals & Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Point-of-Care
    • 7.4.1. Point-of-Care Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Others
    • 7.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Company Market Position Analysis/ Heap Map Analysis
  • 8.3. Company Profiles
    • 8.3.1. Merck & Co., Inc.
      • 8.3.1.1. Participant's Overview
      • 8.3.1.2. Financial Performance
      • 8.3.1.3. Product Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. Elanco
      • 8.3.2.1. Participant's Overview
      • 8.3.2.2. Financial Performance
      • 8.3.2.3. Product Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. Boehringer Ingelheim GmbH
      • 8.3.3.1. Participant's Overview
      • 8.3.3.2. Financial Performance
      • 8.3.3.3. Product Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. Ceva Sante Animale
      • 8.3.4.1. Participant's Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Product Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. Zoetis
      • 8.3.5.1. Participant's Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Product Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. Virbac
      • 8.3.6.1. Participant's Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Product Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. IDEXX
      • 8.3.7.1. Participant's Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Product Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. Mars Inc.
      • 8.3.8.1. Participant's Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Product Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. Dechra Pharmaceuticals Plc (EQT)
      • 8.3.9.1. Participant's Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Product Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. Vetoquinol S.A.
      • 8.3.10.1. Participant's Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Product Benchmarking
      • 8.3.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 U.S. Companion Animal Health market, by animal type, 2018 - 2030 (USD Million)
  • Table 3 U.S. Companion Animal Health market, by product, 2018 - 2030 (USD Million)
  • Table 4 U.S. Companion Animal Health market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 5 U.S. Companion Animal Health market, by end use, 2018 - 2030 (USD Million)
  • Table 6 Participant's overview
  • Table 7 Financial performance
  • Table 8 Product benchmarking
  • Table 9 Strategic Initiatives

List of Figures

  • Fig. 1 Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Commodity Flow Analysis
  • Fig. 9 U.S. Companion Animal Health market revenue, 2018 - 2030 (USD Million)
  • Fig. 10 U.S. Companion Animal Health market snapshot
  • Fig. 11 U.S Companion Animal Health market driver impact
  • Fig. 12 U.S Companion Animal Health market restraint impact
  • Fig. 13 Porter's 5 Forces Analysis
  • Fig. 14 PESTEL Analysis
  • Fig. 15 U.S Companion Animal Health market animal type key takeaways (USD Million)
  • Fig. 16 U.S Companion Animal Health market: animal type movement analysis
  • Fig. 17 U.S dogs market, 2018 - 2030 (USD Million)
  • Fig. 18 U.S cats market, 2018 - 2030 (USD Million)
  • Fig. 19 U.S equine market, 2018 - 2030 (USD Million)
  • Fig. 20 U.S others market, 2018 - 2030 (USD Million)
  • Fig. 21 U.S Companion Animal Health product key takeaways (USD Million)
  • Fig. 22 U.S Companion Animal Health market: product movement analysis
  • Fig. 23 U.S biologics market, 2018 - 2030 (USD Million)
  • Fig. 24 U.S vaccines market, 2018 - 2030 (USD Million)
  • Fig. 25 U.S Modified/ Attenuated Live market, 2018 - 2030 (USD Million)
  • Fig. 26 U.S Inactivated (Killed) market, 2018 - 2030 (USD Million)
  • Fig. 27 U.S Other vaccines market, 2018 - 2030 (USD Million)
  • Fig. 28 U.S other biologics market, 2018 - 2030 (USD Million)
  • Fig. 29 U.S pharamceuticals market, 2018 - 2030 (USD Million)
  • Fig. 30 U.S parasiticides market, 2018 - 2030 (USD Million)
  • Fig. 31 U.S Anti-infectives market, 2018 - 2030 (USD Million)
  • Fig. 32 U.S Anti-inflammatory market, 2018 - 2030 (USD Million)
  • Fig. 33 U.S Analgesics market, 2018 - 2030 (USD Million)
  • Fig. 34 U.S supplements market, 2018 - 2030 (USD Million)
  • Fig. 35 U.S diagnostics market, 2018 - 2030 (USD Million)
  • Fig. 36 U.S others market, 2018 - 2030 (USD Million)
  • Fig. 37 U.S Companion Animal Health market distribution channel key takeaways (USD Million)
  • Fig. 38 U.S Companion Animal Health market: distribution channel movement analysis
  • Fig. 39 U.S retail market, 2018 - 2030 (USD Million)
  • Fig. 40 U.S e-commerce market, 2018 - 2030 (USD Million)
  • Fig. 41 U.S Hospital/ Clinic Pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 42 U.S Companion Animal Health market end use key takeaways (USD Million)
  • Fig. 43 U.S Companion Animal Health market: end use movement analysis
  • Fig. 44 U.S Hospitals & Clinics market, 2018 - 2030 (USD Million)
  • Fig. 45 U.S Point-of-Care market, 2018 - 2030 (USD Million)
  • Fig. 46 U.S others market, 2018 - 2030 (USD Million)
  • Fig. 47 Market participant categorization
  • Fig. 48 Heat map analysis/Company market position analysis